ES2196308T3 - Derivado de 2-cianoiminoimidazol que inhiben la pde iv. - Google Patents
Derivado de 2-cianoiminoimidazol que inhiben la pde iv.Info
- Publication number
- ES2196308T3 ES2196308T3 ES97910380T ES97910380T ES2196308T3 ES 2196308 T3 ES2196308 T3 ES 2196308T3 ES 97910380 T ES97910380 T ES 97910380T ES 97910380 T ES97910380 T ES 97910380T ES 2196308 T3 ES2196308 T3 ES 2196308T3
- Authority
- ES
- Spain
- Prior art keywords
- rent
- replaced
- hydrogen
- halo
- trifluorometilo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 HEPTANYL Chemical class 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical class O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- UCPBYQVLXUIDCK-UHFFFAOYSA-N imidazol-2-ylidenecyanamide Chemical compound N#CN=C1N=CC=N1 UCPBYQVLXUIDCK-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE 2 CIANOIMINOIMIDAZOL DE FORMULA (I), A SUS FORMAS DE N - OXIDO, SUS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES Y SUS FORMAS ESTEREOQUIMICAMENTE ISOMERICAS, DONDE R 1 Y R 2 CADA UNO I NDEPENDIENTEMENTE, SON HIDROGENO, ALQUILO C 1-6 , DIFLUOROMETILO, TRIFLUOROMETILO, CICLOALQUILO C 3-6 , UN HETEROCIC LO DE 5, 6 O 7 MIEMBROS, QUE CONTIENE UNO O DOS HETEROATOMOS SELECCIONADOS A PARTIR DE OXIGENO, AZUFRE O NITROGENO; INDANILO; 6,7 - DIHIDRO - 5H - CICLOPENTAPIRIDINILO; BICICLO[2.2.1] - 2 - HEPTENILO; BICICLO[2.2.1]HEPTANILO; ALQUILSULFONILO C 1-6 ; ARILSULFONILO O ALQUILO C 1-10 SUSTITUIDO; R 3 ES HIDROGENO, HALO O ALQUILOXI C 1-6 ; R 4 ES HIDROGENO, HALO, ALQUILO C 1-6 , TRIFLUOROMETILO; CICLOALQUILO C SUB,3-6 ; CARBOXILO; ALCOXICARBONILO C 1-4 ; CICLOALQUILAMINO CARBONILO C 36 ; ARILO; HET 1 ; O ALQUILO C 1-6 SUSTITUIDO; O R 4 ES - O - R 7 O - NH - R 8 ; R S UP,5 ES HIDROGENO, HALO, HIDROXILO, ALQUILO C 1-6 O ALQUILOXI C 1-6 ; R 6 ES HIDROGENOO ALQUILO C 1-4 ; O R 4 Y R 6 O R 4 Y R 5 , CONJUNTAMENTE, PUEDEN FORMAR UN RADICAL BIVALENTE; - A - B - ES - CR 10 = CR 11 - O - CHR 10 CHR 11 -; L ES HIDROGENO; ALQUILO C 1-6 ; ALQUILCARBONILO C 1-6 ; ALQUILOXICARBONI LO C 1-6 ; ALQUILO C 1-6 SUSTITUIDO; ALQUENILO C 3-6 ; ALQUENILO C 3-6 SUSTITUIDO; PIPERIDINILO; PIPERIDIN ILO SUSTITUIDO; ALQUILSULFONILO C 1-6 O ARILSULFONILO. DICHOS COMPUESTOS PRESENTAN ACTIVIDAD INHIBIDORA DE PDE IV Y DE CITOQUINA. LA INVENCION SE REFIERE TAMBIEN A LOS PROCEDIMIENTOS DE PREPARACION DE LOS COMPUESTOS DE FORMULA (I) Y A COMPOSICIONES FARMACEUTICAS DE LOS MISMOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96202749 | 1996-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2196308T3 true ES2196308T3 (es) | 2003-12-16 |
Family
ID=8224456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97910380T Expired - Lifetime ES2196308T3 (es) | 1996-10-02 | 1997-09-24 | Derivado de 2-cianoiminoimidazol que inhiben la pde iv. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6051718A (es) |
| EP (1) | EP0934280B1 (es) |
| JP (1) | JP3068208B2 (es) |
| KR (1) | KR100520002B1 (es) |
| CN (1) | CN1106387C (es) |
| AR (1) | AR008875A1 (es) |
| AT (1) | ATE236884T1 (es) |
| AU (1) | AU719561B2 (es) |
| BG (1) | BG64278B1 (es) |
| BR (1) | BR9712256B1 (es) |
| CA (1) | CA2267322C (es) |
| CY (1) | CY2380B1 (es) |
| CZ (1) | CZ297474B6 (es) |
| DE (1) | DE69720757T2 (es) |
| DK (1) | DK0934280T3 (es) |
| EE (1) | EE03825B1 (es) |
| ES (1) | ES2196308T3 (es) |
| HU (1) | HU225158B1 (es) |
| IL (2) | IL129298A0 (es) |
| MY (1) | MY116980A (es) |
| NO (1) | NO312960B1 (es) |
| NZ (1) | NZ334971A (es) |
| PL (1) | PL194673B1 (es) |
| PT (1) | PT934280E (es) |
| RU (1) | RU2180902C2 (es) |
| SI (1) | SI0934280T1 (es) |
| SK (1) | SK285878B6 (es) |
| TR (1) | TR199900732T2 (es) |
| UA (1) | UA62939C2 (es) |
| WO (1) | WO1998014432A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK284468B6 (sk) | 1998-04-01 | 2005-04-01 | Janssen Pharmaceutica N. V. | Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy |
| US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
| US7476688B2 (en) | 2001-04-19 | 2009-01-13 | Eisai R&D Management Co., Ltd. | Cyclic amidine derivatives |
| WO2002094320A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Therapeutic compositions for repairing chondropathy |
| DE60234031D1 (de) * | 2001-07-11 | 2009-11-26 | Nikken Chemicals Co Ltd | Mittel zur behandlung allergischer augenerkrankungen |
| TWI221838B (en) | 2001-08-09 | 2004-10-11 | Tanabe Seiyaku Co | Pyrazinoisoquinoline compound or naphthalene compound |
| DK1463493T3 (da) | 2001-12-14 | 2008-02-04 | Serono Lab | Fremgangsmåder til at inducere æglösning ved anvendelse af en ikke polypeptid-cAMP-niveaumodulator |
| JP4549970B2 (ja) | 2003-02-19 | 2010-09-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 環状ベンズアミジン誘導体の製造方法 |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| CA2875964C (en) * | 2012-06-07 | 2018-01-02 | Georgia State University Research Foundation, Inc. | Seca inhibitors and methods of making and using thereof |
| GB2533925A (en) * | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| CN109438434B (zh) * | 2018-11-19 | 2021-05-04 | 华南农业大学 | 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0784461B2 (ja) * | 1986-12-19 | 1995-09-13 | 日本バイエルアグロケム株式会社 | 殺虫性ニトロイミノ又はシアノイミノ化合物 |
| JPH05310650A (ja) * | 1991-08-22 | 1993-11-22 | Nippon Soda Co Ltd | 新規なアミン誘導体、その製造方法及び殺虫剤 |
| ES2227519T3 (es) * | 1992-07-28 | 2005-04-01 | Aventis Pharma Limited | Inhibidores de c-amp-fosfodiesterasa. |
| BR9307570A (pt) * | 1992-12-02 | 1999-05-25 | Pfizer | Diéteres de catecol como inibidores seletivos de pdeiv |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| ES2176251T3 (es) * | 1993-07-28 | 2002-12-01 | Aventis Pharma Ltd | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). |
| JPH09502170A (ja) * | 1993-08-19 | 1997-03-04 | スミスクライン・ビーチャム・コーポレイション | フェネチルアミン化合物 |
| GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
| CA2193725A1 (en) * | 1994-06-24 | 1996-01-04 | David Cavalla | Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity |
| TW332201B (en) * | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
| TW375612B (en) * | 1995-04-06 | 1999-12-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same |
| TW424087B (en) * | 1995-04-06 | 2001-03-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives |
-
1997
- 1997-09-24 UA UA99031702A patent/UA62939C2/uk unknown
- 1997-09-24 PT PT97910380T patent/PT934280E/pt unknown
- 1997-09-24 EP EP97910380A patent/EP0934280B1/en not_active Expired - Lifetime
- 1997-09-24 JP JP10516215A patent/JP3068208B2/ja not_active Expired - Lifetime
- 1997-09-24 SK SK344-99A patent/SK285878B6/sk not_active IP Right Cessation
- 1997-09-24 HU HU9904063A patent/HU225158B1/hu unknown
- 1997-09-24 AU AU47792/97A patent/AU719561B2/en not_active Expired
- 1997-09-24 BR BRPI9712256-4A patent/BR9712256B1/pt not_active IP Right Cessation
- 1997-09-24 CA CA002267322A patent/CA2267322C/en not_active Expired - Lifetime
- 1997-09-24 CZ CZ0102899A patent/CZ297474B6/cs not_active IP Right Cessation
- 1997-09-24 PL PL97332573A patent/PL194673B1/pl unknown
- 1997-09-24 US US09/147,925 patent/US6051718A/en not_active Expired - Lifetime
- 1997-09-24 RU RU99109032/04A patent/RU2180902C2/ru active
- 1997-09-24 CN CN97198460A patent/CN1106387C/zh not_active Expired - Lifetime
- 1997-09-24 DK DK97910380T patent/DK0934280T3/da active
- 1997-09-24 AT AT97910380T patent/ATE236884T1/de active
- 1997-09-24 ES ES97910380T patent/ES2196308T3/es not_active Expired - Lifetime
- 1997-09-24 IL IL12929897A patent/IL129298A0/xx active IP Right Grant
- 1997-09-24 KR KR10-1999-7001204A patent/KR100520002B1/ko not_active Expired - Lifetime
- 1997-09-24 DE DE69720757T patent/DE69720757T2/de not_active Expired - Lifetime
- 1997-09-24 SI SI9730550T patent/SI0934280T1/xx unknown
- 1997-09-24 WO PCT/EP1997/005322 patent/WO1998014432A1/en not_active Ceased
- 1997-09-24 TR TR1999/00732T patent/TR199900732T2/xx unknown
- 1997-09-24 NZ NZ334971A patent/NZ334971A/xx not_active IP Right Cessation
- 1997-09-24 EE EEP199900112A patent/EE03825B1/xx unknown
- 1997-10-01 AR ARP970104528A patent/AR008875A1/es active IP Right Grant
- 1997-10-02 MY MYPI97004600A patent/MY116980A/en unknown
-
1999
- 1999-03-01 BG BG103220A patent/BG64278B1/bg unknown
- 1999-03-30 NO NO19991560A patent/NO312960B1/no not_active IP Right Cessation
- 1999-03-31 IL IL129298A patent/IL129298A/en not_active IP Right Cessation
-
2003
- 2003-11-04 CY CY0300074A patent/CY2380B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69710319D1 (de) | Para-substituierte phenylpropansäure derivate als integrin-antagonisten | |
| ES2150918T3 (es) | 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas. | |
| TR200102136T2 (tr) | Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler. | |
| NO20020725D0 (no) | Celleadhesjonsinhibitorer | |
| DK0928788T3 (da) | Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler | |
| NO985228L (no) | 2,4-diaminopyrimidin-derivater som dopamin D4 resepto-antagonister | |
| SE0300120D0 (sv) | Novel compounds | |
| NO178259C (no) | Amidinoforbindelser, farmasöytiske preparater inneholdende dem samt deres anvendelse i fremstilling av farmasöytiske preparater | |
| TR199900732T2 (xx) | PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri. | |
| MX9204858A (es) | Mejoras en derivados de 2-(piperazinoalquil)indol condensados en posiciones 1,7, asi como un procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos. | |
| NO921159L (no) | Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer | |
| DE69720966D1 (de) | Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren | |
| ES543788A0 (es) | Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo piridinometoxi sustituido y de sus sales deadicion acidas y cuaternarias | |
| MY117936A (en) | 1,3-dihydro-2h-imidazol-2-one derivatives | |
| ATE244258T1 (de) | Halo-derivate von 9-deoxo-9a-aza-9a- homerythromycin a | |
| ES543793A0 (es) | Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo piperidinopropanolico sustituido y sus sa- les de adicion acidas y amonicas cuaternarias | |
| DK0570850T3 (da) | Benzo(b)thiophen-3-yl-piperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
| NO165593C (no) | Analogifremgangsmaate ved fremstilling av nye tetracykliske indolderivater. | |
| NO20053302D0 (no) | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. | |
| DE69000806D1 (de) | Indol-derivate. | |
| FR2823749B1 (fr) | Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant |